SOUTH SAN FRANCISCO, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Sunesis
Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical
company focused on the development and commercialization of novel oncology
therapeutics, today announced upcoming data and corporate presentations.
Voreloxin mechanism of action data and interim data from the company's ongoing
Phase 1 clinical trial of SNS-314 in patients with advanced solid tumors will
be presented at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and
Cancer Therapeutics." Updated interim data from Sunesis' ongoing Phase 2
clinical trial of voreloxin in platinum-resistant ovarian cancer patients will
be presented during the 12th Biennial Meeting International Gynecologic Cancer
Society. Sunesis will also present a corporate presentation at the BIO
Investor Forum. Following are the details on each of these presentations.
EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics,
Geneva, Switzerland
Thursday, October 23
Poster Presentation
Abstract: 283
Title: "Phase 1 Trial of SNS-314, a Novel Selective Inhibitor of Aurora
Kinases A, B, and C, in Advanced Solid Tumor Patients"
Time: 8:00 a.m. CEST / 2:00 a.m. EDT
Friday, October 24
Poster Presentation
Abstract: 598
Title: "Voreloxin (formerly SNS-595) is a Potent DNA Intercalator and
Topoisomerase II Poison that Induces Cell Cycle Dependent DNA Damage and
Rapid Apoptosis in Cancer Cell Lines"
Time: 8:00 a.m. CEST / 2:00 a.m. EDT
12th Biennial Meeting International Gynecologic Cancer Society, Bangkok,
Thailand
Saturday, October 25
Poster Presentation
Abstract: 1607
Title: "A Phase 2 Trial of Voreloxin (SNS-595) in Women with
Platinum-Resistant Ovarian Cancer"
Time: 8:00 a.m. UCT / Friday, 9:00 p.m. EDT
Upcoming Corporate Presentation
BIO Investor Forum
Palace Hotel, San Francisco
Wednesday, October 29, 2008
3:45 p.m. PT
Interested parties may access a webcast of the BIO Investor Forum
presentation by visiting the Sunesis website at http://ir.sunesis.com. A
replay of the webcast will be archived on the "Calendar of Events" page in the
Investors and Media section of the Sunesis website for two weeks.
About Voreloxin
Voreloxin is a first-in-class naphthyridine analog, a chemical structure
closely related to that of the quinolone antibacterial agents. Voreloxin
exerts potent anti-cancer activity through a mechanism that involves
intercalation into DNA and an inhibition of topoisomerase II activity that
results in replication-dependent, site-selective double-strand breaks in DNA
followed by G2 arrest and apoptosis. Voreloxin is currently being evaluated
as a single agent in a Phase 2 clinical trial (known as the REVEAL-1 trial) in
previously untreated elderly patients with acute myeloid leukemia (AML), in a
Phase 1b/2 clinical trial combining voreloxin with cytarabine for the
treatment of patients with relapsed/refractory AML, and as a single agent in a
Phase 2 clinical trial in platinum-resistant ovarian cancer. In clinical
trials conducted to date, voreloxin has been generally well tolerated and has
shown objective responses in both solid and hematologic tumor types.
About SNS-314
SNS-314, a potent and selective pan-Aurora kinase inhibitor, is being
studied in a Phase 1 dose-escalating clinical trial in patients with advanced
solid tumors.
About Sunesis Pharmaceuticals
Sunesis is a clinical-stage biopharmaceutical company focused on the
development and commercialization of new oncology therapeutics for the
treatment of solid and hematologic cancers. Sunesis has built a highly
experienced cancer drug development organization committed to advancing its
lead product candidate, voreloxin, in multiple indications to improve the
lives of people with cancer. For additional information on Sunesis
Pharmaceuticals, please visit http://www.sunesis.com.
SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.
SOURCE Sunesis Pharmaceuticals, Inc.
